Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Conditions
Interventions
Omadacycline
Moxifloxacin
Locations
140
United States
Site 514
Birmingham, Alabama, United States
Site 501
Mobile, Alabama, United States
Site 508
Laguna Hills, California, United States
Site 505
Ventura, California, United States
Site 513
Stamford, Connecticut, United States
Site 511
Zachary, Louisiana, United States
Start Date
November 1, 2015
Primary Completion Date
February 5, 2017
Completion Date
March 10, 2017
Last Updated
January 16, 2019
NCT06804096
NCT07004049
NCT06162286
NCT07386912
NCT05531149
NCT06996834
Lead Sponsor
Paratek Pharmaceuticals Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions